ADL/Metabolomic Technologies' PolypDx Urine-Based Diagnostic Test

Atlantic Diagnostic Laboratories has launched Metabolomic Technologies' PolypDx, a non-invasive urine-based test for detection of adenomatous polyps, the precursor to colorectal cancer. PolypDx only requires a small urine sample for analysis. In a Canadian clinical trial the test demonstrated significantly higher sensitivity than a current fecal-based screening test to detect adenomatous polyps, the company said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.